{"url_path":"/sec/cprx/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001369568-26-000002-index.html","accession_number":"0001369568-26-000002","cik":"0001369568","ticker":"CPRX","issuer_name":"CATALYST PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001369568-26-000002-index.html","primary_entity_key":"0001369568","primary_entity_name":"CATALYST PHARMACEUTICALS, INC."},"word_count":170,"has_tables":true,"body_markdown":"ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS\n\nIssuer Purchases of Equity Securities\n\nIn October 2025, the Company’s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $200 million of the Company’s common stock, pursuant to a repurchase plan under Rule 10b-18 of the Securities Act. The share repurchase program commenced on October 1, 2025 and currently expires on December 31, 2026.\n\nThe following table presents information regarding repurchases by us of our common stock under the Share Repurchase Program during the three months ended March 31, 2026:\n\nPeriod\n\n \n\nTotal\nNumber\nof Shares\nPurchased\n\n \n\n \n\nAverage\nPrice\nPaid Per\nShare\n\n \n\n \n\nTotal\nNumber of\nShares\nPurchased as\nPart of\nPublicly\nAnnounced\nProgram\n\n \n\n \n\nMaximum\nDollar Value\nof Shares that\nMay Yet Be\nPurchased\n(in thousands)\n\n \n\nJanuary 1 - January 31, 2026\n\n \n\n \n\n443,852\n\n \n\n \n\n$\n\n23.43\n\n \n\n \n\n \n\n443,852\n\n \n\n \n\n$\n\n164,299\n\n \n\nFebruary 1 - February 28, 2026\n\n \n\n \n\n171,913\n\n \n\n \n\n$\n\n24.27\n\n \n\n \n\n \n\n171,913\n\n \n\n \n\n$\n\n160,127\n\n \n\nMarch 1 - March 31, 2026\n\n \n\n \n\n—\n\n \n\n \n\n$\n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n$\n\n160,127\n\n \n\nTotal\n\n \n\n \n\n615,765\n\n \n\n \n\n \n\n \n\n \n\n \n\n615,765"}